Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

ge, reaching 4% of the population over 80. Mean age of onset is around 60 years, although in 5-10% of cases the onset is earlier and occurs between the ages of 20 and 50. Primary symptoms include decreased motor function caused by appearance of tremor, rigidity, bradykinesia, and postural instability.  Many patients co-morbidly exhibit impaired cognitive function, depression and excessive day time sleepiness. Dopamine replacement therapies, such as L-DOPA, are the current treatments of choice. However, with time on drug and with disease progression, these drug therapies often lose effectiveness and can cause unwanted side effects such as dyskinesias and hallucinosis.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS).  Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's disease and Alzheimer's disease, cognitive deficits in schizophrenia, depression and female sexual dysfunction, and other disorders pertaining to Women's Health.  To aid in the development process, ITI incorporates its CNSProfile™, a state-of-the-art platform that allows the Company to choose compounds with the strongest potential to succeed in these difficult to treat diseases.


'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... United States in ... More Than a Decade, ... in diagnostic imaging, announced today that the U.S. Food,and Drug Administration ... intravenous use in,T1-weighted magnetic resonance imaging (MRI) of the liver to ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
... CFO-level financial and management services for technology and biotechnology companies, today ... office. Strickland is the latest partner to join the company's Boston ... ... Cambridge, MA (PRWEB) July 8, 2008 -- TechCFO, a leading ...
Cached Biology Technology:FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. Theoretical ... how these organisms should decide how best to preserve ... is quite adaptable. It moves about in liquids and ... can stick to an underlying substrate. Actually, the bacteria ...
(Date:4/15/2014)... April 15, 2014, Irvine, Calif. UC Irvine neurobiologists have ... when transplanted into the brains of mice with the symptoms ... in the journal Stem Cells Research and Therapy , ... different mouse models. , Alzheimer,s disease, one of the ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from the ... to selective serotonin reuptake inhibitors (SSRIs), a frequently prescribed ... with autism spectrum disorder (ASD) and developmental delays (DD) ... of Pediatrics , analyzed data from large samples ...
Breaking Biology News(10 mins):Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2
... be best known for their supersized canines, but they also ... fatal bite, says a new study in the journal ... extinct cat Smilodon fatalis roamed North and South ... as bison, camels, mastodons and mammoths. Telltale clues from bones ...
... While pregnant women may worry about the effects of air ... exposure to carbon monoxide and fine particles in the air ... preterm delivery or preeclampsia -- a serious condition that arises ... headed by a University at Buffalo epidemiologist. , The ...
... cell decide its particular identity? According to biologists at ... of T cellsimmune system cells that help destroy invading ... particular gene called Bcl11b. The activation of Bcl11b ... have decided to go on the T-cell pathway," says ...
Cached Biology News:Why you should never arm wrestle a saber-toothed tiger 2Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Caltech biologists discover how T cells make a commitment 2Caltech biologists discover how T cells make a commitment 3
BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...
HOXC11 Antibody...
HOXC11 Antibody...
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: